Clinical Practice Guidelines for the Management of
Erectile Dysfunction

Dr.Joe's Data Base

We welcome all contributions to this
database. We are particularly interested in your anecdotal
experience.

 

Clinical Practice Guidelines for the Management of
Erectile Dysfunction


An "evidence-supported" Canadian consensus document


Contributors


+ Michael A. Adams, MD, Moderator

+ Brewer Auld, MD

+ Gerald Brock, MD

+ Francois Benard, MD

+ Rosemary Basson, MD

+ Serge Carrier, MD

+ Michael Chetner, MD

+ John Collins, MD

+ Michael Condra, MD

+ Ms. Janet Fenemore

+ Jerzy Gajewski, MD

+ Jeremy P.W. Heaton, MD

+ Sender Herschorn, MD

+ Mrs. Brenda Johnston

+ Alvaro Morales, MD


-------------------------------------------------------------------------
--


CONTENTS


1. Nomenclature


2. Physiology of Erection


3. Office Diagnosis


4. Patient goal-directed therapy


5. The non-invasive pharmacologic treatment of erectile
dysfunction


6. Intracavernous injection (ICI) therapy


7. Treatment with vacuum devices


8. Penile prosthetics


9. Vascular surgery


10. Nursing aspects


11. Acknowledgments


12. Additional information


-------------------------------------------------------------------------
--


PREAMBLE


This document summarizes the current state of knowledge of
erectile

dysfunction (ED) and defines some principles of diagnosis and
treatment.

The original material was submitted by a panel of Canadian
experts drawn

from across the country. This material was put together and a
composite

document discussed in Ottawa in June 1995.

-------------------------------------------------------------------------
--


NOMENCLATURE


Erectile Dysfunction is preferred to the common form
"impotence", as

directed by the N.I.H. Consensus Conference on Impotence,
1992.(1) ED is

defined as the persistent inability to gain or maintain a
penile erection

sufficient for sexual intercourse. ED is a defined problem
and should be

distinguished from premature ejaculation, other orgasmic
dysfunction, and

Peyronie s disease.

-------------------------------------------------------------------------
--


PHYSIOLOGY OF ERECTION


The basic essential elements of a normal erection with an
appropriate

stimulus will remain unchallenged:


1. An adequate nervous system.


2. Adequate arterial inflow.


3. A functioning veno-occlusive mechanism.


4. Functional penile anatomy.


5. An adequate hormonal environment.


6. Mind focussed on the sexual stimulus, freedom from
distractions, and

from fear of an unrewarding outcome.


The understanding of the physiological basis for erectile
function is
under

continuous revision. Much is known about the function of
penile smooth

muscle,(2) the role of neurotransmitters,(3) the anatomical
and
structural

elements,(4) and the basis of central nervous system
control.(5) Much
will

change and be refined over the next half-decade. See Appendix
for more

details.

-------------------------------------------------------------------------
--


OFFICE DIAGNOSIS


Office evaluation is initially directed to characterizing the
exact
nature

of the sexual problem and developing a rapport that will be
the
foundation

of successful management. Patient comfort and cooperation are
reinforced
by

the examiner's facility in discussing sexual problems, using

easily-understood terminology.


Male erectile dysfunction, changes in sexual desire, and
orgasmic

disturbances are frequently believed to be synonymous by both
patients
and

referring persons. Each of these areas should be carefully
explored and

distinguished as a separate entity.


History


+ Sexual History (Appendix B contains an acceptable but
non-validated

form of history.(6)

+ Partner and relationship issues;

+ Other medical problems: diseases, prior surgery, and
medications.


Physical Exam


+ General health

+ The genitalia should be routinely examined, including the
testes for

size and consistency and the penis for deformities, scars, or
plaques.

+ Secondary sexual characteristics;

+ Digital rectal exam (DRE).

+ More detailed examination of the relevant region or system
when

indicated.


Psychological Assessment


Especially important when there is situational variation in
erectile

ability (for details, see Appendix A).


+ Intrapersonal problems (e.g., performance anxiety);

+ Interpersonal problems (e.g., marital);

+ Coexistent psychiatric disease;

+ History of addiction;

+ History of abuse or violence.


Laboratory There are no mandatory laboratory tests.


Serum testosterone (morning value) determination is useful.


Serum prolactin when libido is depressed.


Full endocrinologic assessment is indicated in cases of
secondary

hypogonadism.


Karyotyping, if there is a basis for suspicion.


RBS or, preferably, glycosylated hemoglobin is indicated in
diabetics.


Supplementary formal investigations


+ Nocturnal penile tumescence (NPT);

+ Dynamic infusion cavernosometry and cavernosography (DICC);

+ Dynamic Doppler ultrasound studies;

+ Selective arteriography (only if arterial surgery or PCTA
is

contemplated);

+ Biothesiometry.


-------------------------------------------------------------------------
--


PATIENT GOAL-DIRECTED THERAPY


The therapy for ED has a somewhat different basis, when
compared with the

treatment of many other diseases. It is not life-threatening,
and
although

commonly physical in origin, it can have significant
psychological impact

on both partners and has a potential for a widespread effect
in many

socioeconomic domains. Sexual activity, by its nature, is
intermittent
and

generally involves a partner whose support is vital to the
success of the

therapy. The patient and partner must be sufficiently
motivated to get

involved in a form of therapy. For couples to be satisfied
with
treatment,

it is imperative that both partners have a thorough
understanding of the

problem and realistic expectations of the possible solutions
(See
Appendix

A).


* Goal-directed therapy - an algorithm


-------------------------------------------------------------------------
--


THE NON-INVASIVE PHARMACOLOGIC TREATMENT OF ERECTILE
DYSFUNCTION


The treatment of erectile dysfunction should be tailored to
the patient's

specific needs and expectations, i.e.,
"goal-directed". Non-invasive

therapy includes the careful elimination of erectolytic
agents (drugs
that

prevent erection). Currently, no medication fulfils the
criteria of the

"ideal" agent for the treatment of ED, which would
be:


1. effective;


2. useful "on demand";


3. free of side effects;


4. easy to administer;


5. affordable.


The agent should be specific for the etiology of the
dysfunction.

Unfortunately, the only ones in this category are hormonal
supplementation

agents.


Hormonal


Testosterone Specifically indicated for the treatment of
hypogonadic

states. Its use is restricted for patients with biochemical
evidence of

hypotestosteronemia. There are injectable, oral, and
transdermal

preparations.


a. Injectable esters: 200 to 300 mg I.M. every two to three
weeks. Safe
but

has a "roller-coaster" effect.


b. Oral: the undecanoate is readily absorbed by the gut and
is free of

liver toxicity; 120 to 160 mg daily. Methylated forms carry
significant

liver toxicity.


c. Transdermal (currently not available in Canada): One or
two patches
with

daily application to the shaved scrotum or skin.


Neuropharmacologic


Useful as a first-line treatment for a limited trial period.


1. Yohimbine. An alpha-2 adrenoceptor antagonist, with
limited

effectiveness. Useful on a trial basis during the evaluation
process.

Currently used orally at 10 mg (or near equivalent) t.i.d.


2. Phentolamine. Also an adrenoceptor antagonist. Most
commonly used for

intracavernosal injection. Difficult to obtain for buccal
administration,

20 to 40 mg "on demand".


3. Trazodone. A serotoninergic agonist with some adrenoceptor
antagonistic

properties. Uses at oral doses 50 to 150 mg at bedtime or 50
mg t.i.d.

Early evidence suggests a synergism with yohimbine.


Peripheral vasodilators


1. Nitroglycerin paste. Applied to the penile shaft, produces
modest

increases in tumescence but not usable rigidity.


2. L-arginine. In limited trials, has been reported to be
effective. It
is

readily available.


3. Minoxidil. Initial enthusiasm has vanished with results of
controlled

studies.


4. Prostaglandin E1. Recent reports suggest it may be
effective by

intra-urethral application. Not yet commercially available.


There are a number of other compounds under investigation.
However,
results

of limited trials must be taken with much caution. It should
be
remembered

that it is unlikely that systemic administration of drugs
would prove to
be

effective in the presence of major alterations of penile
physiology.


-------------------------------------------------------------------------
--


INTRACAVERNOUS INJECTION (ICI) THERAPY


A program of ICI should be implemented as an integral part of
a

goal-directed assessment of sexual and erectile dysfunction,
with
suitable

education and follow-up. The prescribing physician should
therefore have

special competence in the use of potent vasoactive agents on
an ad hoc

basis.


Indications


+ Patient choice;

+ Failure of less invasive therapy.


Contraindications


+ Proven problem with allergic response to the medications
proposed;

+ Patients in whom significant systemic changes in blood
pressure
would

have grave consequences;

+ Patients with an inability to inject themselves (or be
injected by
a

partner) safely.


Relative Contraindications


+ Sickle-cell disease;

+ Patients at risk for subacute bacterial endocarditis;

+ History of idiopathic priapism;

+ Poor compliance, e.g., drug dependency.


Agents


Single agent:


* PGE1: a rapidly metabolized vasoactive prostaglandin; PGE1
is the

only agent with FDA approval for ICI.


Combination (based on one or more of the following agents):


+ Phentolamine: an alpha adrenoceptor blocker;

+ Papaverine;

+ PGE1;

+ Triple therapy (PGE1, papaverine, phentolamine).


The mixture required for this should comply with good
standards of
pharmacy

preparation, and the shelf-life of the mixture should be
defined. Use of
a

single agent from a single-dose vial may be considered
optimal from the

quality control standpoint.


Doses and titration


+

+ Determined by the precise mixtures;

+ Between 0.2 and 1 mL for the initial injection;

+ Doses depend entirely on the actual combinations;

+ Suggested starting dose for PGE1 is 2.5 micrograms;

+ Increments of 2.5 micrograms until achievement of a
satisfactory

response;

+ Benefits of doses exceeding 20 micrograms are small and the
risk of

systemic effects increases.(7)


The starting dose of any preparation should be reduced for
those
suspected

of having a primary neurogenic cause. The suggested starting
dose is one

half of the usual starting dose for any local mixture, and
1.25
micrograms

for PGE1 alone.


Potential side effects


+ Priapism: increases with the amounts of compound injected.

Phentolamine is associated with an increased rate of priapism
(see

Appendix for treatment);

+ Pain on injection;

+ Penile fibrosis (<1%);

+ Systemic pressure changes which should not occur with
appropriate,

regular use, but may from time to time be associated with

intracavernosal injection;

+ Bruising is uncommon. Injection may be used in people on
concurrent

anticoagulant therapy;

+ Appropriate use of intracavernosal injection may improve
spontaneous

erectile function. Suggested frequency of use of
intracavernosal

therapy is up to three times per week.


-------------------------------------------------------------------------
--


TREATMENT WITH VACUUM DEVICES


High-quality vacuum devices have relatively few adverse
effects and are

effective alternatives to more invasive and complex
treatments.

Constriction rings used with the vacuum devices can sometimes
be used

alone, in order to maintain erections in men where premature
detumescence

is the major complaint. These vacuum devices can also be used
in

conjunction with intracorporeal injections to produce and
maintain

functional erections.


VED erections 1. Tumescence occurs only distal to the
constriction band
and

may cause some pivoting of the phallus.


2. The skin temperature of the penis decreases an average of
one degree

Celsius for each 30 minutes the constriction ring is in
place, due to

decreased arterial blood flow [3].


3. The vacuum causes some engorgement of extracorporeal
penile tissue,

resulting in a larger-than-normal circumference erection [4].


Adverse effects


1. Some initial minor pain or discomfort is not uncommon, but
it usually

dissipates with ongoing use.(8)


2. Ecchymosis or petechiae of the penile skin occurs in 12 to
25% of

patients, but is self-limiting and resolves without
intervention.


3. The sensation of climax is unaffected, but antegrade
ejaculation is

often impeded due to occlusion of the urethra by the
constriction
band.(9)


4. The device is relatively contra-indicated in men on
anticoagulants or

with blood dyscrasias.


Efficacy


These devices produce erections sufficient for intercourse in
73 to 100%
of

men who use them.(10) Individualized patient education and
instruction on

the proper use of vacuum devices, coupled with help in
overcoming the few

potential difficulties encountered in using them, improve
patient

satisfaction with this technique of treating erectile
impotence.


-------------------------------------------------------------------------
--


PENILE PROSTHETICS


Since the late 1970s, prosthetic penile implantation has been
a very

successful means of treating organic erectile dysfunction.
Penile

prostheses are mechanical devices that produce a firm penis.
They may not

necessarily reproduce the patient's former erections in size
or rigidity.


Indications


1. Patients who are refractory to other forms of treatment;


2. Patient preference, with concurrence of physician.


Types 1. Malleable rod;


2. Self-contained inflatable;


3. Two-piece inflatable;


4. Three-piece inflatable.


Device selection There is no single prosthesis that is the
best for every

patient. The following factors should be considered in
selecting a
device:

patient age, medical status, penile and scrotal size, manual
dexterity,

personality, social activity, and economic status.


+ Malleable rod: lowest possibility of mechanical failure;
good
choice

for older patients and patients with significant medical
problems;

possible problem of concealment.

+ Three-piece inflatable: most complete flaccidity on
deflation; on

inflation, potential to increase in length as well as girth,
giving

perhaps a more natural erection; more extensive operative

procedure.(11)

+ One-piece inflatable: inflation and deflation appearance
very

similar; little advantage over malleable type, for patients
with
short

penis; selected indicators where other prostheses
contraindicated.

+ Two-piece inflatable: potential to give benefits of
three-piece

inflatable type, with less extensive surgery.(12)


Complications


Rates of mechanical complications are quite acceptable.
Meticulous

attention to technical detail before, during, and after
surgery is

important in maintaining surgical complications at their
current low

rates.(13) An awareness of the susceptibility of certain
groups (revision

surgery, diabetics, spinal cord-injured patients) to
infection is vital
to

proper patient selection and preparation for surgery.


Outcome Overall patient and partner satisfaction is high with
all types
of

prostheses.(14) Important factors that lead to these good
results are

proper patient selection and appropriate counselling to
create realistic

expectations for outcome.


-------------------------------------------------------------------------
--


VASCULAR SURGERY


Vascular deficiency causing ED may be arterial, venous, or
both. Many

operations have been devised to restore arterial inflow and
decrease
venous

outflow, but the published studies have all been
retrospective and are

based frequently on differing inclusion criteria, workups,
and outcome

measures. The successful results reported in expert hands,
however,
justify

the ongoing evaluation of these surgical techniques. Vascular
surgery

should, therefore, probably be restricted to centers with
expertise.


Venous Surgery Corporeal veno-occlusive dysfunction or venous
insufficiency

may be primary or secondary and the result of smooth muscle
dysfunction,

abnormal perforating veins, collagen degeneration intunica,
or incomplete

smooth muscle relaxation.


+ Diagnosis

+ Dynamic infusion cavernosometry and cavernosography after
ICI;

+ Cavernosography may demonstrate leakage into dorsal,
cavernous, or

crural veins. Opacification of the glans is considered
physiological;

+ Duplex ultrasonography may also be performed, to rule out
arterial

insufficiency.

+ Therapy (VED with or without ICI may be effective)

+ "Venous leak" surgery: considered experimental by
many authorities.

+ Transluminal venous embolization and sclerosis.

+ Results

+ Cure rates of 10 to 50%;

+ Tend to decline with length of follow-up;

+ Complications seen are penile edema, hematoma,
hypoesthesia, and

shortening. The incidence of complications ranges from 0 to
46%.


Arterial Surgery


Cavernosal artery insufficiency is most commonly the result
of

atherosclerosis. The condition results in lowered rigidity of
the erect

penis and prolonged time to maximum erection. It may be a
sole cause of
or

contributing factor to the erectile dysfunction.


Another recently described and seemingly common cause is
blunt perineal

trauma.


+ Diagnosis

+ Sudden onset of weak erections after blunt perineal trauma;

+ ICI is the most commonly used screening test;

+ Duplex ultrasonography after ICI;

+ DICC may be performed to determine concomitant venous
insufficiency;

+ Internal pudendal super selective arteriography with ICI.

+ Treatment (ICI, VED, and penile implants are non-specific
but

effective)

+ Revascularization: usually reserved for post-pelvic or
perineal

trauma;

+ The results are uncertain, because of unstandardized
diagnostic
tests

and unobjective and uncontrolled postoperative follow-up
methods
used

for reporting.


-------------------------------------------------------------------------
--


NURSING ASPECTS


A nurse coordinator, in cooperation with the physician and
team, can

improve the quality of intervention and create a
comprehensive supporting

program for:


a. Patient education;


b. Counselling;


c. Support for patient and partner;


d. Diagnostic testing;


e. Treatment.


Experience has shown that few patients present clear-cut
single-factor

cases of ED. The final diagnosis is not uncommonly different
from the
first

impression, as there are often complex psychosocial and
medical issues

involved that only emerge as confidence builds. A
well-trained and

knowledgeable nurse can supplement historical information and
coordinate

the couple's management.

November 13, 1996
19:55 +0000

This is an important campaign. Please write to Bush House, The
Strand, London.

  Home page Search Page Table
of Contents

 


1